Moderna's Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson's drug

Fortune · 35

Cellular Intelligence added Moderna co-founder Bob Langer and AI researcher Yann LeCun to its scientific advisory board and Langer also joined as an observer on its board to guide AI-driven cell-behavior modeling for drug development. The company acquired global rights to STEM-PD, a Phase 2-ready Parkinson’s cell therapy with FDA Fast Track designation. As a result, Cellular Intelligence will continue advancing STEM-PD while plans to license its models for paid drug-discovery work and develop additional medicines using its AI foundation model and new biological data engine.